NCT06282510View on ClinicalTrials.gov

Nasal Antisepsis for C. Auris Prevention

PHASE4RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 29, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Candida Auris InfectionColonization, Asymptomatic
Interventions
DRUG

Povidone Iodine Topical

Topical intranasal povidone iodine (10%) twice daily for 5 days

Trial Locations (3)

60521

RECRUITING

RML Specialty Hospital, Hinsdale

60612

RECRUITING

Rush University Medical Center, Chicago

60624

RECRUITING

RML Specialty Hospital, Chicago

All Listed Sponsors
collaborator

Rush University Medical Center

OTHER

collaborator

RML Specialty Hospital

OTHER

lead

Mary K Hayden

OTHER